Open Access Highly Accessed Open Badges Research article

Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1) – distinct characteristics in neurons

Annina Lyly1, Carina von Schantz1, Tarja Salonen1, Outi Kopra2, Jani Saarela13, Matti Jauhiainen1, Aija Kyttälä1 and Anu Jalanko1*

Author affiliations

1 Department of Molecular Medicine, National Public Health Institute, Biomedicum Helsinki, P.O.BOX 104, Haartmaninkatu 8, FIN-00251 Helsinki, Finland

2 Department of Medical Genetics and Neuroscience Center, Folkhälsan Institute of Genetics, Biomedicum Helsinki, FIN-00014 University of Helsinki, Finland

3 Department of Medical Biochemistry, Medical University of Vienna, Dr. Bohr Gasse 9, A-1030 Vienna, Austria

For all author emails, please log on.

Citation and License

BMC Cell Biology 2007, 8:22  doi:10.1186/1471-2121-8-22

Published: 12 June 2007



Neuronal ceroid lipofuscinoses (NCLs) are collectively the most common type of recessively inherited childhood encephalopathies. The most severe form of NCL, infantile neuronal ceroid lipofuscinosis (INCL), is caused by mutations in the CLN1 gene, resulting in a deficiency of the lysosomal enzyme, palmitoyl protein thioesterase 1 (PPT1). The deficiency of PPT1 causes a specific death of neocortical neurons by a mechanism, which is currently unclear. To understand the function of PPT1 in more detail, we have further analyzed the basic properties of the protein, especially focusing on possible differences in non-neuronal and neuronal cells.


Our study shows that the N-glycosylation of N197 and N232, but not N212, is essential for PPT1's activity and intracellular transport. Deglycosylation of overexpressed PPT1 produced in neurons and fibroblasts demonstrates differentially modified PPT1 in different cell types. Furthermore, antibody internalization assays showed differences in PPT1 transport when compared with a thoroughly characterized lysosomal enzyme aspartylglucosaminidase (AGA), an important observation potentially influencing therapeutic strategies. PPT1 was also demonstrated to form oligomers by size-exclusion chromatography and co-immunoprecipitation assays. Finally, the consequences of disease mutations were analyzed in the perspective of our new results, suggesting that the mutations increase both the degree of glycosylation of PPT1 and its ability to form complexes.


Our current study describes novel properties for PPT1. We observe differences in PPT1 processing and trafficking in neuronal and non-neuronal cells, and describe for the first time the ability of PPT1 to form complexes. Understanding the basic characteristics of PPT1 is fundamental in order to clarify the molecular pathogenesis behind neurodegeneration in INCL.